Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Language
Publication year range
1.
J Allergy Clin Immunol ; 149(2): 718-727, 2022 02.
Article in English | MEDLINE | ID: mdl-34331992

ABSTRACT

BACKGROUND: Mast cells (MCs) have a profound impact on allergic asthma. Under such conditions, MCs undergo degranulation, resulting in the release of exceptionally large amounts of MC-restricted proteases. However, the role of these proteases in asthma is only partially understood. OBJECTIVES: We sought to test our hypothesis that MC proteases can influence the functionality of human lung fibroblasts (HLFs). METHODS: Primary HLFs were treated with MC chymase or tryptase, followed by assessment of parameters related to fibroblast function. RESULTS: HLFs underwent major morphologic changes in response to chymase, showing signs of cellular contraction, but were refractory to tryptase. However, no effects of chymase on HLF viability or proliferation were seen. Chymase, but not tryptase, had a major impact on the output of extracellular matrix-associated compounds from the HLFs, including degradation of fibronectin and collagen-1, and activation of pro-matrix metalloprotease 2. Further, chymase induced the release of various chemotactic factors from HLFs. In line with this, conditioned medium from chymase-treated HLFs showed chemotactic activity on neutrophils. Transcriptome analysis revealed that chymase induced a proinflammatory gene transcription profile in HLFs, whereas tryptase had minimal effects. CONCLUSIONS: Chymase, but not tryptase, has a major impact on the phenotype of primary airway fibroblasts by modifying their output of extracellular matrix components and by inducing a proinflammatory phenotype.


Subject(s)
Asthma/etiology , Chymases/toxicity , Fibroblasts/drug effects , Lung/drug effects , Mast Cells/enzymology , Apoptosis/drug effects , Cells, Cultured , Collagen Type I/metabolism , Fibroblasts/metabolism , Fibroblasts/pathology , Humans , Lung/metabolism , Lung/pathology , Mast Cells/physiology , Transcriptome , Tryptases/toxicity
2.
Biol Pharm Bull ; 41(9): 1355-1361, 2018 Sep 01.
Article in English | MEDLINE | ID: mdl-29910215

ABSTRACT

The intestinal barrier dysfunction is a critical pathological change in irritable bowel syndrome (IBS). The objective of this study was to evaluate the effect of Prim-O-glucosylcimifugin (POG) on intestinal barrier dysfunction and reveal possible molecular mechanisms. Human colon adenocarcinoma cell line (Caco-2) cell monolayers induced by tryptase (TRYP) were used to establish an intestinal barrier dysfunction model. Caco-2 cell monolayers from both functional and dysfunctional samples were treated with POG (30, 60 and 120 µg/mL) for 2, 8, 24, 36, 48 and 72 h. The Caco-2 cell monolayers were assessed by measurement of trans-epithelial electrical resistance (TEER) and percentage of fluorescein permeation (PFP). The expression of Protease Activated Receptor 2 (PAR-2) and myosin light chain kinase (MLCK) mRNA was analyzed by RT-PCR and the level of Zonula Occludens-1 (ZO-1) protein expression was determined by Western blot. In addition, the impact of POG on the distribution of the tight juction protein of Occludin was performed by immunofluorescence. Our results showed that POG elevated the TEER and decreased the PFP of the functional Caco-2 cell monolayers, as well as the dysfunctional Caco-2 cell monolayers. Furthermore, POG inhibited the expression of PAR-2 mRNA and MLCK mRNA and increased the level of ZO-1 protein expression in dysfunctional Caco-2 cells. The distribution of the Occludin proteins was ameliorated simultaneously. This study demonstrates that POG can enhance the intestinal barrier function of Caco-2 cell monolayers by inhibiting the expression of PAR-2 and MLCK and up-regulating the expression of ZO-1 protein, and ameliorated the distribution of Occludin protein.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Intestinal Absorption/drug effects , Intestinal Mucosa/drug effects , Monosaccharides/pharmacology , Tryptases/toxicity , Xanthenes/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Caco-2 Cells , Cell Survival/drug effects , Cell Survival/physiology , Dose-Response Relationship, Drug , Humans , Inflammation Mediators/agonists , Inflammation Mediators/antagonists & inhibitors , Inflammation Mediators/metabolism , Intestinal Absorption/physiology , Intestinal Mucosa/metabolism , Monosaccharides/chemistry , Tight Junctions/drug effects , Tight Junctions/physiology , Xanthenes/chemistry
3.
J Biol Chem ; 292(3): 1061-1067, 2017 01 20.
Article in English | MEDLINE | ID: mdl-27932459

ABSTRACT

Basophils have often been erroneously considered to be minor relatives or blood-circulating precursors of tissue-resident mast cells because of some phenotypic similarity between them, including basophilic secretory granules in the cytoplasm. However, recent studies revealed that the repertoire of serine proteases stored in secretory granules is distinct in them. Particularly, mouse mast cell protease 8 (mMCP-8) is specifically expressed by basophils but not mast cells despite its name. Therefore, mMCP-8 is commonly used as a basophil-specific marker, but its functional property remains uncertain. Here we prepared recombinant mMCP-8 and examined its activity in vitro and in vivo Purified recombinant mMCP-8 showed heat-sensitive proteolytic activity when α-tubulin was used as a substrate. One intradermal shot of mMCP-8, not heat-inactivated, induced cutaneous swelling with increased microvascular permeability in a cyclooxygenase-dependent manner. Moreover, repeated intradermal injection of mMCP-8 promoted skin infiltration of leukocytes, predominantly neutrophils and, to a lesser extent, monocytes and eosinophils, in conjunction with up-regulation of chemokine expression in the skin lesion. These results suggest that mMCP-8 is an important effector molecule in basophil-elicited inflammation, providing novel insights into how basophils exert a crucial and non-redundant role, distinct from that played by mast cells, in immune responses.


Subject(s)
Dermatitis/enzymology , Inflammation/enzymology , Leukocytes/metabolism , Mast Cells/enzymology , Skin/metabolism , Tryptases/metabolism , Animals , Dermatitis/genetics , Dermatitis/pathology , Inflammation/chemically induced , Inflammation/genetics , Inflammation/pathology , Leukocytes/pathology , Mast Cells/pathology , Mice , Mice, Inbred BALB C , Mice, Knockout , Skin/pathology , Tryptases/genetics , Tryptases/toxicity , Tubulin/genetics , Tubulin/metabolism
5.
Vet Dermatol ; 20(2): 105-10, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19159412

ABSTRACT

There are numerous studies of the pruritus-producing effects of histamine, serotonin, tryptase, substance P and interleukin-2 in humans and mice, but very little reported in dogs even though a common reason dogs are presented to veterinarians is pruritus. The aim of this study was to determine whether substances known to cause pruritus in humans also cause pruritus in dogs. Twenty-five clinically healthy research beagle dogs were included in the study. All dogs first received an intradermal injection of 0.05 mL saline as a control substance and were video-recorded for 20 min before and after the injection. Twenty-four hours later the dogs were randomly divided into five groups of five dogs each and randomly assigned to receive histamine, serotonin, tryptase, substance P or interleukin-2 injected intradermally each at the volume of 0.05 mL. On subsequent days, increasing concentrations of each substance were used. Before (baseline) and after the injection of each concentration of the substances, the dogs were video-recorded for 20 min. The frequency and character of pruritus episodes (scratching, licking, chewing, rubbing or rolling) were noted and these data were used for statistical analysis. The number of pruritus episodes was compared among baseline, saline and the different concentrations of each substance. The results showed that dogs did not have a significant increase in pruritic behaviour above baseline or saline after injection of any of the investigated substances (generalized linear model; P = 0.23).


Subject(s)
Histamine/toxicity , Interleukin-2/toxicity , Pruritus/veterinary , Serotonin/toxicity , Substance P/toxicity , Tryptases/toxicity , Analgesics, Non-Narcotic/toxicity , Animals , Dog Diseases/chemically induced , Dogs , Female , Histamine Agonists/toxicity , Neurotransmitter Agents/toxicity , Pruritus/chemically induced , Serotonin Agents/toxicity
SELECTION OF CITATIONS
SEARCH DETAIL
...